New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:08 EDTINSYInsys backs Q2 revenue view of over $52M, consensus $52.77M
Insys Therapeutics reaffirmed its revenue guidance for Q2 ended June 30. Revenue from sales of Subsys is expected to exceed $52M for the quarter, as compared with $18.5M during 2Q13.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:14 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, CBD, for the treatment of glioma, which comprises approximately eighty percent of all malignant brain tumors. The ODD includes pontine glioma, a devastating form of primary brainstem glioma.
September 26, 2014
10:03 EDTINSYInsys Therapeutics receives orphan status for glioma treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use